When in doubt, keep it light or skip
Providers retain full discretion to prescribe or decline compounded GLP-1 medications
Meanwhile, Hanyu Pharmaceutical confirmed that Phase III clinical trials for both weight management and hypoglycemic indications of semaglutide have been initiated, with all subjects already enrolled, receiving dosing and follow-ups, and entering the final stage, with clinical trials expected to be completed within 2025
Andrew Huberman, a well-respected neuroscientist, has shared valuable insights into various supplements that can enhance cognitive function, improve mood, and support overall health
However, anecdotal reports from clinical practices suggest that many patients achieve meaningful weight loss at doses well below the maximum